Phase 2 N=8 Prevention

Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)

Aging

Bottom Line

View on ClinicalTrials.gov: NCT02865499 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2019

Primary outcome: Primary: Change in Microbiome — 0; 0; 0 Operational Taxonomic Unit (OTU)

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: acarbose (Drug)
Age: Older Adult · 70+ yrs
Sex: All
Sponsor: The University of Texas Health Science Center at San Antonio
Primary completion: Oct 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Microbiome	0; 0; 0	—

Summary

This study addresses a "lifespan approach to healthy development and aging" with direct relevance to humans by testing the anti-aging effects of acarbose in humans. It is a pilot study to: i) better estimate power for a larger trial, ii) establish the safety and potential beneficial effects of acarbose in non-diabetic elderly humans, and iii) determine whether the effects of acarbose on the microbiome likely play a role in its enhancement of longevity and/or healthy aging. These are essential initial steps for translating acarbose into an anti-aging human therapy.

Eligibility Criteria

Inclusion Criteria

age 70-95
participants will be in good health with all chronic diseases (hypertension, coronary artery disease, etc.) clinically stable.
participants must have adequate cognitive function to be able to give informed consent. This will be established by enrolling participants with CLOX 1 scores of ≥10.

Exclusion Criteria

unstable ischemic heart disease
clinically significant pulmonary disease
history of immunodeficiency or receiving immunosuppressive therapy
history of a coagulopathy or receiving a medical condition requiring anticoagulation
an estimated glomerular filtration rate of 350mg/dl;
uncontrolled hypertriglyceridemia >500mg/dl
diabetes
history of skin ulcers or poor wound healing
smoking
liver disease treatment with drugs known to affect cytochrome P450 3A (diltiazem, erythromycin)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02865499). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.